Adenocarcinoma of the Pancreas Recruiting Phase 1 / 2 Trials for Gemcitabine (DB00441)

Also known as: Adenocarcinoma, Pancreatic / Adenocarcinoma of Pancreas / Pancreas Adenocarcinoma / Adenocarcinoma, Pancreas / Pancreatic Adenocarcinoma / Pancreas, Adenocarcinoma / Adenocarcinoma Pancreas

IndicationStatusPhase
DBCOND0029532 (Adenocarcinoma of the Pancreas)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04060342GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaTreatment
NCT04257448Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.Treatment
NCT036788839-ING-41 in Patients With Advanced CancersTreatment
NCT03193190A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Treatment
NCT03745430RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaTreatment